Understanding Vaccine-Induced Immunogenicity and Safety: A Comparative Study

by

Introduction

COVID-19 has resulted in an unprecedented production of vaccines at a rate that is record-breaking. Several vaccines have come out with different platforms. The major platforms include the mRNA and viral vector platforms and the inactivated virus platform. Once millions of people around the world are taking these vaccines, the immunogenicity and safety profiles of each become imperative. Antigenicity and reactogenicity are the immunological properties of a vaccine, while the safety, or the frequency and seriousness of side effects of a vaccine they can trigger, define the efficacy and uptake of a vaccine. In this article, the author undertakes a comparative review of different COVID-19 vaccines in terms of their immunogenicity and safety in clinical trials.

Immunogenicity of COVID-19 Vaccines

It still calls for attention to how immunogenic the vaccine is, that is, how well it elicits one of the cornerstones of the immune response to the threat of the virus: the production of neutralizing antibodies that can prevent the virus from entering cells. Comparing the existing COVID-19 vaccines, there can be a marked contrast in the level of immunogenicity of different vaccines, which can be explained by the nature of the technology the vaccines were based on.

Some of the new vaccines include the Pfizer/BioNTech vaccine, BNT162b2, and the Moderna vaccine, mRNA-1273, which have yielded decent immunogenicity. These vaccines introduce the spike protein of the SARS-CoV-2 virus, whereby upon the activation of the host cells these proteins are produced and an immune response ensues. Phase 3 studies have proved that these vaccines elicit a moderately high level of neutralizing antibodies similar to those of those who recover from COVID-19 disease. This immunogenicity has been seen for children and a group of people considered to be relatively difficult to immunize the elderly.

On the other hand, the category of Vaccines includes viral vector vaccines such as Ad26. COV2. S (Johnson & Johnson) and ChAdOx1 nCoV-19 (AstraZeneca) work on the principle of using a human adenovirus vector that carries the gene of the spike protein into cells. These vaccines have also proven to have high immunogenicity, though the immune response elicited by some of them is associated with lower titers than those of mRNA vaccines. It is still sufficient to prevent severe disease, which means other strategies for immunological protection are involved, for instance, a cellular immunity mediated by T-helper cells.

Whole virus vaccines, as seen in Sinopharm and Sinovac vaccines, display the complete virus to the immune system, but the virus is negatively inactivated and is therefore harmless. These vaccines have given positive responses and produced neutralizing antibodies, often at somewhat lower levels than mRNA and viral vector vaccines. However, these vaccines have been safe and provided good immune responses in the various population groups as covered here.

Yearwise Publication Trend on “immunogenicity”

Find publication trends on relevant topics

Safety Profiles of COVID-19 Vaccines

The other factor that is a major consideration when assessing vaccines is safety, as some side effects affect the perception and acceptance of the vaccines. The safety profiles of COVID-19 vaccines differ, and while most vaccines have revealed quite a good safety margin, most adverse events are mild to moderate.

BNT162b2 and mRNA-1273 have been investigated in countless numbers of participants, and doses have been administered globally. The side effects include local irritation that may manifest as pain at the site of injection or systemic reactions including fever, fatigue, and headache. These symptoms are often transient and usually last for not more than five days. This is true for serious adverse events, which are however infrequent but include myocarditis, especially among young males. Thus, all in all, the odds are in favor of the benefit-risk ratio, although such incidents are rare.

Some of the known COVID-19 vaccines are viral vector vaccines such as Ad26. COV2. S and ChAdOx1 nCoV-19 have demonstrated a favorable tolerability profile, and they have similar mild to moderate adverse effects to the mRNA vaccines. However, a small increased risk of coagulation disorders, specifically CVST, has been reported with these vaccines, albeit at a rare occurrence that makes it cause temporary bans or alter the recommendations on its use among some population sub-groups. However, the frequency of such occurrences is quite low, and the advantages of taking a vaccine against COVID-19 are many.

Some of the side effects that have been experienced with inactivated virus vaccines include the following: these adverse events appear to be even fewer and less serious than those that have been associated with the mRNA and viral vector vaccines. Common adverse effects were observed at the site of injection and mild pyrexia. There has been no serious concern that emanated from the trials and other subsequent rollouts of these vaccines; hence, they could be considered viable, particularly given the risks of adverse events following immunization through other types of vaccines in those populations.

Comparative Analysis

Indeed, some general or more specific observations can be made as concerns the immunogenicity and the safety profiles of each of these vaccines. mRNA vaccines are also more effective regarding immunogenicity, with higher titers of neutralizing antibody production. This may translate into better protection, especially for variants of concern as has been seen in the case of B.1.351. But they also generally appear to stimulate more severe reactogenicity and more frequent systemic adverse events such as fever and fatigue.

As we have seen earlier, viral vector vaccines are comparatively low in immunogenicity but still provide solid protection against severe manifestations of COVID-19. They also have the prerogative of being easy to transport and capable of being stocked, hence outcompeting the mRNA vaccines that require ultra-cold chains. Some serious but low-incidence side effects, including blood clotting disorders, have contributed to the changes in approach to the vaccines.

Inactivated virus vaccines give a different form of balance, and while their side effects are generally mild, their antibody production is relatively low. But since they can deliver the entire viral protein, they can stimulate a more massive immune response; their effectiveness may last longer; in addition, they can protect against variants of the virus.

Recent Publications on “immunogenicity”

Find publications on relevant topics

Future Perspectives

With this in mind, several challenges make emergency-spaced-based vaccination strategies increasingly important as COVID-19 progresses. An assessment of the differences in immunogenicity and safety between vaccines enables researchers to make useful conclusions to be applied in the subsequent formation of subsequent generations of vaccines. Future booster doses and surveillance for the effectiveness of vaccines, including the new variants, will play a significant role in the future vaccination strategy. In the same way, the generation of second or third-generation vaccines that may incorporate the favorable characteristics of different platforms or may have the potential to neutralize multiple variants at the same time could also improve the prospects for pandemic control.

However, one must appreciate the outcomes associated with the firmness and immunogenicity of these vaccinations in the long run. Over time, with extended follow-up and data from real-world studies, we will have a better appreciation of not only their long-term efficacy but also efficacy by race and ethnicity, as well. This will help not only for a further, deeper understanding of booster vaccine measures but also for the creation of new kinds of vaccines that have wider overall protection and more durability.

Conclusion

All the COVID-19 vaccines that have been developed up to date have high immunogenicity and safety profiles, each with its advantages and limitations. mRNA vaccines take the lead in generating good amounts of antibodies, and viral vector vaccines provide very effective immune responses against severe forms of the disease, provided the logistical challenges. The other approach of inactivated virus vaccination has been described as rather conventional and associated with a favorable safety profile. Although the pandemic is far from over, more studies and practical data will be needed to improve the process of vaccination and make sure that everyone is protected from COVID-19 in all its variations.

References

  1. Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B. and Offergeld, K., 2021. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine, 384(23), pp.2187-2201.
  2. Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B. and McGettigan, J., 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England journal of medicine, 384(5), pp.403-416.
  3. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C. and Bailey, R., 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine, 383(27), pp.2603-2615.
  4. Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W. and Yang, Y., 2020. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama, 324(10), pp.951-960.
  5. Wang, Z.J., Zhang, H.J., Lu, J., Xu, K.W., Peng, C., Guo, J., Gao, X.X., Wan, X., Wang, W.H., Shan, C. and Zhang, S.C., 2020. Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. Emerging microbes & infections, 9(1), pp.2606-2618.
  6. Maeda, H., Saito, N., Igarashi, A., Ishida, M., Suami, K., Yagiuchi, A., Kimura, Y., Komino, M., Arai, H., Morikawa, T. and Motohashi, I., 2022. Effectiveness of messenger RNA coronavirus disease 2019 vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 infections during the delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). Clinical Infectious Diseases, 75(11), pp.1971-1979.
  7. Reis, B.Y., Barda, N., Leshchinsky, M., Kepten, E., Hernán, M.A., Lipsitch, M., Dagan, N. and Balicer, R.D., 2021. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. New England Journal of Medicine, 385(22), pp.2101-2103.

Top Experts on “immunogenicity“